Analysts call Gilead a takeover target

Will Gilead Sciences continue to stand alone, or will it fall prey to buyout like its neighbors Chiron and Genentech? The company is dominant in the HIV market and is also exploring hear and lung disease treatments. Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.